Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: Findings from randomized clinical trials

被引:13
作者
Colli, Enrico
Parazzini, Fabio
Olivieri, Lorenza
Cipriani, Sonia
Bertozzi, Rosanna
Meschia, Michele
Montorsi, Francesco
机构
[1] BioXell Spa, I-20090 Milan, Italy
[2] Univ Milan, Clin Ostetr Ginecol 2, Fdn Policlin Mangiagalli Regina Elena, Milan, Italy
[3] Ist Ric Farmacol Mario Negri, Milan, Italy
[4] UO Ginecol & Ostetricia, Milan, Italy
[5] Osped San Raffaele, Urol Clin, Milan, Italy
关键词
number of micturitions; overactive bladder; volume voided;
D O I
10.1016/j.eururo.2007.03.070
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To analyze the relationship between mean volume voided per micturition and number of daytime micturitions. Methods: We reviewed data from randomized clinical trials on the medical treatment of overactive bladder published in the international literature between 1997 and 2004. Fourteen studies including data on these two parameters were identified. Results: Six studies compared tolterodine with placebo, two tolterodine and oxybutynin with placebo, two tolterodine with oxybutynin, two solifenacin and tolterodine with placebo, one oxybutynin CR with oxybutynin IR, and one different doses of solifenacin. The correlation between the percent change in the mean voided volume and in the number of daytime micturitions was assessed using the Spearman rank correlation coefficient (r), with r = -0.67 for all the studies. For groups of patients treated with each drug, we found r = -0.09 for oxybutynin, r = -0.59 for tolterodine, r = -0.85 for solifenacin, and r = -0.34 for placebo. Conclusion: The results of this analysis suggest that in the evaluation of the efficacy of a drug for overactive bladder, the mean volume voided per micturition may be a useful measure of efficacy. (C) 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 27 条
[1]  
Abrams P, 1998, BRIT J UROL, V81, P801
[2]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[3]   Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence [J].
Anderson, RU ;
Mobley, D ;
Blank, B ;
Saltzstein, D ;
Susset, J ;
Brown, JS .
JOURNAL OF UROLOGY, 1999, 161 (06) :1809-1812
[4]   A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence [J].
Barkin, J ;
Corcos, J ;
Radomski, S ;
Jammal, MP ;
Miceli, PC ;
Reiz, JL ;
Harsanyi, Z ;
Darke, AC .
CLINICAL THERAPEUTICS, 2004, 26 (07) :1026-1036
[5]   Behavioral vs drug treatment for urge urinary incontinence in older women - A randomized controlled trial [J].
Burgio, KL ;
Locher, JL ;
Goode, PS ;
Hardin, JM ;
McDowell, BJ ;
Dombrowski, M ;
Candib, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (23) :1995-2000
[6]   Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder [J].
Cardozo, L ;
Lisec, M ;
Millard, R ;
Trip, OV ;
Kuzmin, I ;
Drogendijk, TE ;
Huang, M ;
Ridder, AM .
JOURNAL OF UROLOGY, 2004, 172 (05) :1919-1924
[7]   Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms [J].
Chancellor, M ;
Freedman, S ;
Mitcheson, HD ;
Antoci, J ;
Primus, G ;
Wein, A .
CLINICAL DRUG INVESTIGATION, 2000, 19 (02) :83-91
[8]   The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis [J].
Chapple, C ;
Khullar, V ;
Gabriel, Z ;
Dooley, JA .
EUROPEAN UROLOGY, 2005, 48 (01) :5-26
[9]   A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder [J].
Chapple, CR ;
Roehrborn, CG .
EUROPEAN UROLOGY, 2006, 49 (04) :651-659
[10]   A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial [J].
Chapple, CR ;
Martinez-Garcia, R ;
Selvaggi, L ;
Toozs-Hobson, P ;
Warnack, W ;
Drogendijk, T ;
Wright, DM ;
Bolodeoku, J .
EUROPEAN UROLOGY, 2005, 48 (03) :464-470